TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04652154

Intervention type: OTHER
Group type: OTHER
Intervention: Transitioning young patients' health care trajectories
Description: New intervention where the patient with multi-referrals to specialist health service meet with a complementary professional team consisting of doctor, psychologist and physioterapist aiming clarify the child's condition through shared decison-making and agreeing upon treatment plans for the child

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transitioning young patients' health care trajectories
Description: New intervention where the patient with multi-referrals to specialist health service meet with a complementary professional team consisting of doctor, psychologist and physioterapist aiming clarify the child's condition through shared decison-making and agreeing upon treatment plans for the child
Study: NCT01490853

Intervention type: DRUG
Intervention: Interpheron alpha
Description: Long term outcom after interferon alpha discontinuation or not
Study: NCT00623974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide (Forteo)
Description: Subcutaneous Injection Every 12 Hours for 7 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide (Forteo)
Description: Subcutaneous Injection Every 12 Hours for 7 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide (Forteo)
Description: Subcutaneous Injection Every 12 Hours for 7 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium
Description: 1000 milligrams by mouth (PO) Every 12 Hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium
Description: 1000 milligrams by mouth (PO) Every 12 Hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium
Description: 1000 milligrams by mouth (PO) Every 12 Hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium
Description: 1000 milligrams by mouth (PO) Every 12 Hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: 0.25 micrograms PO Every 12 Hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: 0.25 micrograms PO Every 12 Hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: 0.25 micrograms PO Every 12 Hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: 0.25 micrograms PO Every 12 Hours
Study: NCT03617003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WST11 mediated vascular targeted phototherapy (VTP)
Description: All patients will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes while patients are under anesthesia during their endoscopy procedure, followed by immediate laser light application.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy
Description: Endoscopy of the bladder
Study: NCT01301456

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single subcutaneous injection of placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04856883
Description: Single subcutaneous injection of PF-04856883

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04856883
Description: Single subcutaneous injection of PF-04856883

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04856883
Description: Single subcutaneous injection of PF-04856883

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single subcutaneous injection of placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04856883
Description: Single subcutaneous injection of PF-04856883

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04856883
Description: Single subcutaneous injection of PF-04856883

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04856883
Description: Single subcutaneous injection of PF-04856883

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple weekly subcutaneous injections of placebo for 3 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04856883
Description: Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04856883
Description: Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04856883
Description: Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04856883
Description: Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
Study: NCT04613856

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydration protocol - 237 mL water bolus
Description: Subjects consume 237 mL of water every 20 minutes during 2 hours of high intensity work in the heat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydration protocol - 500 mL water bolus
Description: Subjects consume 500 mL of water every 40 minutes during 2 hours of high intensity work in the heat.
Study: NCT00644553

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Clarithromycin Extended-Release 500 mg tablet (2 tablets QD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin-clavulanate 875/125 mg tablet (1 tablet BID)
Study: NCT02202291

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Demonstration of genetic mutations causing Raynaud's phenomenon
Description: Such an approach allows to highlight chromosomal regions shared only by individuals within a family and thus highlight the genetic mutations causing the Raynaud phenomenon . The ultimate goal is to identify new pathways involved in vasospasm.~Patients with primary Raynaud phenomenon will be identified during a consultation of vascular medicine and internal medicine in one of the centers participating to the study. Those patients with a primary PR will be considered as Index cases.~The investigators will conduct genealogical trees of index cases to identify families, whose number of healthy individuals and those with relevant PR makes sense for a family genetic study, i.e. a genetically informative family.
Study: NCT00404066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1250 mg, tablets, oral daily during treatment with docetaxel (3-week cycles x 4 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with doxorubicin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 100 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg, subcutaneously on day 2 of all cytotoxic chemotherapy treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 300 or 480 mcg, subcutaneously on days 3 to 10 after cytotoxic chemotherapies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8 mg, oral taken twice a day for 3 days starting 24 hours before docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Loading dose 8 mg/kg, then 6 mg/kg, intravenously every 3 weeks for 1 year
Study: NCT00303420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase push protocol
Description: alteplase 2 mg / lumen. Instill and wait 10 minutes, instill 0.3 ml normal saline, wait 10 minutes, instill 0.3 ml of normal saline, wait 10 minutes and aspirate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alteplase dwell arm
Description: alteplase 2 mg / lumen. Instill and let it dwell for 30 minutes. Assess catheter and allow to dwell for a total of 2 hours if necessary
Study: NCT02879604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compensatory cognitive training
Description: In addition to the usual care, method of compensatory cognitive remediation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual
Description: Usual care
Study: NCT01087957

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WalkAide
Description: Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ankle-Foot Orthosis (AFO)
Description: Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
Study: NCT01488279

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 2.5 mg and Sitagliptin 100 mg
Description: Participants received Dexamethasone 2.5mg plus Sitaliptin 100mg daily for 8 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone 2.5 mg and Sitagliptin 100 mg
Description: Participants received Dexamethasone 2.5mg plus Sitaliptin 100mg daily for 8 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 2.5 mg and placebo tablet
Description: Participants rececived Dexamethasone 2.5 mg plus placebo tablet daily for 8 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone 2.5 mg and placebo tablet
Description: Participants rececived Dexamethasone 2.5 mg plus placebo tablet daily for 8 days
Study: NCT02313298

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: IMRT or similar techniques that use inverse treatment planning
Study: NCT04229511

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of CRKp colonization
Description: Detection of CRKp colonization will be performed in all participants by sceening with rectal swab

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of CRKp colonization
Description: Detection of CRKp colonization will be performed in all participants by sceening with rectal swab

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of CRKp colonization
Description: Detection of CRKp colonization will be performed in all participants by sceening with rectal swab
Study: NCT02383290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision support
Description: Saliva samples will be collected from each participant for genetic testing. A genetic report will be fed back to the research server, and into the Family Physicians/pharmacist's electronic record. The electronic record is linked to the UBC TreatGx computer; the next time the participant is seen by the Family Physician / Pharmacist personalized prescribing recommendations will be available for use.
Study: NCT04858984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: A portable, standalone VR headset called Oculus Go (Facebook Technologies, LLC. 1601 Willow Road, Menlo Park, CA 940250) with a head-mounted display with built in audio drivers was used. Disposable hygiene masks and a surgical cap were used as an underlay below the headset an
Study: NCT01969097

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: transcranial direct current stimulation (tDCS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: transcranial direct current stimulation (tDCS)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: transcranial direct current stimulation (tDCS)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor training
Description: Motor training of the affected upper extremity (5 days, 25 min/day).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor training
Description: Motor training of the affected upper extremity (5 days, 25 min/day).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Motor training
Description: Motor training of the affected upper extremity (5 days, 25 min/day).
Study: NCT02678338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hu5F9-G4
Study: NCT00657865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramipril
Description: oral intake

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02745366

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BFPSC+FDBA+PRF

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FDBA+PRF
Study: NCT01098812

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis ZCB00 IOL (control)
Description: Tecnis 1-piece acrylic IOL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric Intraocular lens
Description: Toric acrylic intraocular lens with various cylinder powers

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric Intraocular lens
Description: Toric acrylic intraocular lens with various cylinder powers
Study: NCT01017367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDX-1100
Description: MDX-1100 10 mg/kg i.v. over 60 minutes on days 1, 15, 29, 43, 57 and 71

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05489692

Intervention type: PROCEDURE
Intervention: hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX)
Description: FOLFOX-HAIC as the following dosage: 130 mg/m2 oxaliplatin infusion for 2 hours; 400 mg/m2 of leucovorin infusion for 2 hours; and 400 mg/ m2 of 5-FU bolus and 1200 of mg/m2 continuous infusion of 5-FU for 23 hours.~Patients received targeted therapy, three different targeted therapy were applied including: 1. lenvatinib 2. sorafenib; 3. apatinib. A portion of patients received PD-1 inhibitor administered intravenously every three weeks.
Study: NCT04757441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A: Conventional Treatment + Elongation Longitudinaux Decoaption of Osteo-Articulaire
Description: ELDOA position for L5, S1 level Patient will ask to lie on his back, wedge buttocks in the corner of wall and raise his legs. Then Stretch the legs and push the heels toward ceiling. Extend the spine and stretch the arms above head .~• Patient will hold this position for one minute and repeat it for 4 -5 times.~Conventional treatment will include:~* Hot pack for 15 minutes .~* TENS for 10 minutes .~* self stretching of hamstrings

Intervention type: OTHER
Group type: OTHER
Intervention: Group B: Conventional treatment
Description: Participants will receive only conventional treatment which will include:~* Hot pack for 15 minutes .~* TENS for 10 minutes .~* self stretching of hamstrings
Study: NCT00376090

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-CMDR
Description: 10\^7 PFU IM, 1.0 mL

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.0 mL IM

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.0 mL IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-CMDR
Description: 10\^6 PFU ID, 0.1 mL

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.1 mL ID

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.1 mL ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-CMDR
Description: 10\^8 PFU IM, 1.0 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-CMDR
Description: 10\^7 PFD ID, 0.1 mL
Study: NCT04262050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS)
Study: NCT01200004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m2 subcutaneous or by vein on days 1 - 5 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m2 subcutaneous or by vein on days 1 - 5 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grifola Frondosa
Description: 3 mg/kg by mouth twice a day on days 1 - 21 of a 28 day cycle.
Study: NCT01887951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penthrox Inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol Injection
Study: NCT04587011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan dose A or placebo
Description: Tegoprazan A mg or placebo taken orally twice daily for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan dose B or placebo
Description: Tegoprazan B mg or placebo taken orally twice daily for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan dose C or placebo
Description: Tegoprazan C mg or placebo taken orally twice daily for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan dose D or placebo
Description: Tegoprazan D mg or placebo taken orally twice daily for 3 days.
Study: NCT01627002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PA401
Description: Part A of Study: Subcutaneous, 0.1mg to 50mg, single ascending doses Part B of Study: Subcutaneous, up to 17.1mg, single dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous
Study: NCT00210184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan associated to fluorouracil and leucovorin
Study: NCT00786747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personally tailored computer program
Description: The experimental computer program provides the user with information about colorectal cancer screening that is tailored to their self-efficacy, readiness, and perceived barriers to undergoing screening, in their preferred language (English or Spanish).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-tailored control computer program
Description: This program provides users with non-tailored information about colorectal cancer screening, in their preferred language (English or Spanish).
Study: NCT01444482

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix M
Description: 1 human dose of seasonal influenza vaccine formulated with 50 µg Matrix M, total dosage volume 0.55 mL injected intramuscularly in the upper arm once at day 0.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Seasonal influenza vaccine
Description: 1 human dose of seasonal influenza vaccine
Study: NCT03427567

Intervention type: PROCEDURE
Intervention: Sublobar dissection
Description: Sublobar dissection plus lymphadenectomy
Study: NCT03017638

Intervention type: OTHER
Intervention: Questionaire
Description: Patients undergoing primary laparoscopic colectomy patients under general anesthesia with an additional Quadratus lumborum block (QLB ) will be asked to fill out a questionnaires detailing: numeric verbal analogue scores (VAS) and quality of recovery score(QoR) preoperatively, 24 hours, 48 hour and four weeks after surgery. Additional data will be collected: ASA physical status, demographics, intra- and post operative opiate(expressed as morphine equivalent in mg/kg) and non opiate consumption in order to assess the analgesic efficacy of QLB for primary laparoscopic colectomy. QLB will be performed as per standard routine regimens, in the operating room after induction of general anesthesia and prior to surgery.
Study: NCT02463721

Intervention type: OTHER
Group type: OTHER
Intervention: ascitic fluid culture and microbiological testing
Description: ascitic fluid culture and microbiological testing for 100 patients with liver cirrhosis and ascites with suspicion of SBP
Study: NCT02700152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UltraShape
Description: Tissue selectivity is achieved by a proprietary knowledge of ultrasound parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
Study: NCT03008954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GSP3
Description: Each capsule of GSP3 (previously Attiva) contains 700 mg of a mixture of two food-grade materials: carboxymethylcellulose that is cross-linked with citric acid.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GSP3
Description: Each capsule of GSP3 (previously Attiva) contains 700 mg of a mixture of two food-grade materials: carboxymethylcellulose that is cross-linked with citric acid.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Avicel (modified Cellulose)
Description: Each capsule of Avicel contains approximately 350 mg of microcrystalline cellulose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Avicel (modified Cellulose)
Description: Each capsule of Avicel contains approximately 350 mg of microcrystalline cellulose
Study: NCT02087072

Intervention type: OTHER
Intervention: Collaborative visit with provider and pharmacist
Study: NCT03189862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Skills Intervention
Description: The behavioral motor skills intervention (CHAMP) is an intervention strategy that uniquely addresses differences in children's developmental levels on an individualized basis. CHAMP does not equate to a one size fits all approach. Children will be in an environment that promotes opportunities for them to develop improvements in motor skills based on their specific individual needs and choices. The CHAMP intervention promotes a mastery climate that allows each individual child to be successful and learn while promoting intrinsic motivation and autonomy. CHAMP will be implemented 4x/week for 30 minutes across ≈30 weeks for ≈3000 minutes of intervention time.